Antimicrobial Susceptibility Testing Market projected increase to US$ 5.98 Billion by 2030, reflecting a steady CAGR of 5.23%

Antimicrobial Susceptibility Testing Market Snapshot

“The Antimicrobial Susceptibility Testing Market is estimated to increase at a CAGR of 5.23% from $ 3.78 billion in 2023 to $ 5.98 Billion by 2030.”

Antimicrobial susceptibility testing (AST) is a laboratory procedure used by medical technologists to determine the most effective antimicrobial regimen for specific individuals. It also aids in evaluating treatment services for infectious disease control and prevention.

Researchers have developed continuous surveillance efforts for resistance patterns due to alterations in bacterial DNA. Clinical laboratories use various methodologies, including disc diffusion and minimum inhibitory concentration (MIC) methods, based on their test menu.

Commercial technologies for characterization of bacterial resistance are now available in health centers and hospitals. Routine antimicrobial susceptibility testing for gram-positive and gram-negative bacteria is common in peripheral laboratories, while drug susceptibility testing for Mycobacterium tuberculosis is typically performed in more complex facilities. All laboratories must be critical at every step to ensure high levels of accuracy and reliability in test findings.

The global Antimicrobial susceptibility testing market is influenced by macroeconomic and industrial factors like drug legislation, product licencing, and distribution. The key development is the innovative MALDI-TOF mass spectrometry for quick disease pathogen detection.

The market growth rate of Antimicrobial susceptibility testing is predicted to decrease by 98 basis point share (BPS) in H1-2022, according to a Market Report Service Report analysis, which is 50 BPS lower than the predicted timeframe.

>>>Download Sample Report Now:https://marketreportservice.com/request-sample/antimicrobial-susceptibility-testing-market-54635  

Demand Outlook

Antimicrobial resistance is causing a rise in antimicrobial susceptibility testing, affecting people of all ages and races. The issue causes 2 million infections and 23,000 deaths in the US and 25,000 deaths in Europe, leading to a demand for novel broad-spectrum antibacterial treatments.

The global market size is also expanding due to this growing concern.

Government funding and attention are crucial for product development. The World Health Organisation and non-profit organizations propose a new antimicrobial innovation funding mechanism, which would finance grants and innovation-induced rewards, benefiting upstream innovation, interim trial findings, and finished product outcomes.

Growth Drivers

Rapid AST techniques enable targeted treatment, driving market growth in antibiotic susceptibility testing. The rapid increase in sales of testing devices is attributed to the widespread use of online channels. Vendors in the market are leveraging online marketing and promotional techniques to enhance sales and ensure greater access to their products, thereby driving market expansion.

Automated antibiotic susceptibility testing methods are expensive due to their complex features and functions, reducing incubation and detection periods by 50%. This presents a significant barrier to market growth, especially in smaller medical facilities, due to their complexity.

• The incidence of infectious diseases is on the rise.
• The global rise of multidrug resistance is a significant global issue.

Restraints

Automated antimicrobial susceptibility testing systems offer advanced functionality and reduced detection time, but their high cost may hinder global market growth due to potential hindrance in achieving accurate results.

The National Centre for Biotechnology Information reports that the high cost of molecular testing for antimicrobial susceptibility hinders the implementation of new technologies. This includes clinical sampling and culturing in microbiology labs before antibiotic susceptibility testing (AST).

The total cost for mass spectrometry-based AST is around €79 (US$83.3) per patient, when including the costs of the MALDI-TOF apparatus, reagents, pharmacist time, and antimicrobial stewardship program.

Antimicrobial Susceptibility Testing Market Segment Analysis

The global Antimicrobial Susceptibility Testing Market is dominated by antibacterial segments.

Antibacterial susceptibility testing helps doctors determine which medications affect microorganisms, aiding in the treatment of difficult-to-treat infections. In 2020, isoniazid resistance was documented in 456 cases in the US, accounting for 4.8% of cases among U.S.-born people and 9.5% of cases among non-U.S.-born people.

Government initiatives and product awareness programs drive market expansion, as seen in the 2021 Canadian Antimicrobial Resistance Surveillance System report, which provides an integrated view of national-level data on antimicrobial resistance and use.

In 2022, hospitals and diagnostic centers will dominate the antimicrobial susceptibility testing market, accounting for 63.5%. This segment is projected to grow at a CAGR of 5.7% from USD 2.2 billion in 2022 to USD 2.9 billion by 2027, with the fastest growth rate.

The disc diffusion method is expected to dominate the market by 2022, accounting for 27.4% of all goods, due to its versatility in susceptibility testing for antimicrobial medicines, driven by increasing acceptance and advancements in susceptibility plates.

Dis disc diffusion is a cost-effective, versatile method that offers visibility of development, adequate inoculum, mixed cultures, and other oddities, making it the largest market share among antimicrobial susceptibility test products.

Competitive Landscape of the Antimicrobial Susceptibility Testing Market Analysis

• Bio-Rad Laboratories
• Beckman Coulter
• Thermo Fisher Scientific
• Becton
• Dickinson and Company
• Conda
• Creative Diagnostics
• HiMedia Laboratories
• Alifax Holding S.p.A.
• Biotron Healthcare.

New Developments in Antimicrobial Susceptibility Testing Market

In May 2022, Qualigen Therapeutics announced that NanoSynex Ltd, a company with whom Qualigen recently entered into definitive agreements to acquire a majority stake, featured at BioMed Israel. Innovative Technology by NanoSynex focuses to accelerate antimicrobial susceptibility test results times by six-fold.

In April 2022, COPAN Diagnostics demonstrated its range of fully automated solutions for identification and antimicrobial susceptibility testing (AST) in clinical microbiology at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022). COPAN demonstrated the Food and Drug Administration-cleared Colibri, a fully automated specimen workup instrument designed to prepare MALDI-TOF ID targets and create bacterial suspensions for AST.

In Apr 2022, bioMérieux acquire specific diagnostics. This will help the company to strengthen its commitment to fight antimicrobial resistance.

In Aug 2022, BD, a leading global medical technology company, announced worldwide commercial collaboration with Accelerate Diagnostics, Inc. which will help both the companies to address the global threat of antimicrobial resistance.

For Instance, in 2019, F. Hoffmann-La Roche Ltd., a research-based healthcare company announced the CE-IVD launch of the cobas MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA.

Alifax launched a ground-breaking proper system for rapid bacteria detection that gives antibiotic susceptibility and resistance testing in six hours and needs less manual labour, based on the rapid phenotyping method.

Regional Outlook

The North American market for antimicrobial susceptibility testing is expanding due to increasing demand for empiric treatment, research and development for resistance testing systems, and increasing adoption in medical labs. Major corporations with headquarters in the region prioritize expansion to expand their network and capabilities, driving market growth.

North America is predicted to dominate the antimicrobial susceptibility testing market due to rising antibiotic-resistant illnesses and increased antibiotic use. The COVID-19 pandemic has led to a 150% and 82% increase in azithromycin use in nursing homes, with the trend expected to continue until October 2020.

The antimicrobial susceptibility testing market in Europe is experiencing significant growth due to improved healthcare infrastructure, rising medical demands, and rising antibiotic resistance rates. Government efforts and health insurance policies are expected to drive market growth. Additionally, the global market for antimicrobial susceptibility testing is expanding due to increased awareness of infectious diseases.

The market growth in China is driven by public health concerns and increased over-the-counter antibiotic usage. Additionally, increased financing for antibiotic sensitivity testing processes and the adoption of minimum inhibitory concentration in clinical labs are critical factors for market expansion.

Segments Covered in the Antimicrobial Susceptibility Testing Market Report

By Product Type

• Manual Antimicrobial Susceptibility Testing Products
• Automated Laboratory Instruments
• Consumable

By Application

• Antibacterial
• Antifungal
• Anti-parasitic
• Antiviral

By Method

• Disk Diffusion
• Rapid Automated AST
• Broth Dilution
• Gradient Diffusion
• Genotypic Methods

By End User

• Hospitals
• Pathology/Diagnostic Laboratories
• Research and Academic Institutes
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations

The above information has been provided for the following regions and countries:

North America

• U.S.
• Canada

Europe

• UK
• Germany
• France
• Italy
• Russia

Asia Pacific

• China
• India
• Japan
• South Korea

Latin America

• Brazil
• Mexico

MEA

• UAE
• Saudi Arabia
• South Africa

Frequently Asked Questions

What is the expected growth rate of the Antimicrobial Susceptibility Testing market over the next 7 years?

The Antimicrobial Susceptibility Testing Market is estimated to increase at a CAGR of 5.23% from $ 3.78 billion in 2023 to $ 5.98 Billion by 2030.

Who are the major players in the Antimicrobial Susceptibility Testing market and what is their market share?

Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Conda, Creative Diagnostics, HiMedia Laboratories, Alifax Holding S.p.A., Biotron Healthcare, are prominent players operating and dominating in the market.

What is the demand projection for Antimicrobial Susceptibility Testing by 2030?

Demand for Antimicrobial Susceptibility Testing is projected to reach a market value of US$ 5.98 Billion by 2030-end.

What is the sales growth projection for Antimicrobial Susceptibility Testing?

Revenue from sales of Antimicrobial Susceptibility Testing is projected to increase at a CAGR of 5.23% through 2030.